AcelRx, a biotech developing a Phase 3 treatment for acute post-operative pain, will see its quiet period end on Tuesday, March 22. On February 10, the company raised $40 million by offering 8 million shares at $5, below the range of $12 to $14. Piper Jaffray...read more
AcelRx, a biotech developing a treatment for acute post-operative pain, raised $40 million by offering 8 million shares at $5 per share. Redwood, CA based company, which expects to initiate Phase 3 trials of its lead drug candidate in the second half of 2011,...read more
AcelRx, a biotech developing a Phase 3 treatment for acute post-operative pain, lowered the proposed deal size for its upcoming IPO on Wednesday. The Redwood City, CA-based company now plans to raise $40 million by offering 8 million shares at an estimated...read more
AcelRx quiet period ends March 22
AcelRx, a biotech developing a Phase 3 treatment for acute post-operative pain, will see its quiet period end on Tuesday, March 22. On February 10, the company raised $40 million by offering 8 million shares at $5, below the range of $12 to $14. Piper Jaffray...read more
AcelRx prices IPO at $5, below the original $12-$14 range
AcelRx, a biotech developing a treatment for acute post-operative pain, raised $40 million by offering 8 million shares at $5 per share. Redwood, CA based company, which expects to initiate Phase 3 trials of its lead drug candidate in the second half of 2011,...read more
AcelRx slashes proposed IPO price to $5 per share, now plans to raise $40 million
AcelRx, a biotech developing a Phase 3 treatment for acute post-operative pain, lowered the proposed deal size for its upcoming IPO on Wednesday. The Redwood City, CA-based company now plans to raise $40 million by offering 8 million shares at an estimated...read more
11 IPOs planned for the week of Feb 7
The following IPOs are expected to price this week:
AcelRx (ACRX), a biotech developing a Phase 3 treatment for acute post-operative pain, plans to raise $75 million by...read more